Command Palette

Search for a command to run...

Tier IPhospholipid precursor470 trials

CDP-Choline — The Neuroprotective Phospholipid Precursor

CDP-choline (citicoline) is a naturally occurring intermediate in the synthesis of phosphatidylcholine, a major structural component of cell membranes. In the context of longevity, it is primarily studied for its neuroprotective properties, its ability to support cognitive function during aging, and its role in maintaining cellular membrane integrity.

Mechanism of Action

CDP-choline is hydrolysed in the gut into cytidine and choline, which cross the blood-brain barrier and are reassembled into CDP-choline. It serves as a rate-limiting intermediate in the Kennedy pathway for the biosynthesis of phosphatidylcholine, crucial for neuronal membrane repair. Additionally, it increases the synthesis of acetylcholine, dopamine, and noradrenaline. It also exhibits neuroprotective effects by preserving cardiolipin and sphingomyelin levels, increasing glutathione synthesis, and attenuating the activation of phospholipase A2, thereby reducing the release of pro-inflammatory arachidonic acid.

Human Trial Evidence

Multiple human trials have investigated CDP-choline for age-related cognitive decline and vascular cognitive impairment. The IDEALE study (2013) demonstrated that 1,000 mg/day of oral citicoline was effective and well-tolerated in older adults with mild vascular cognitive impairment. Another randomized, double-blind, placebo-controlled trial (Nakazaki et al., 2021) showed that 500 mg/day of citicoline for 12 weeks significantly improved overall memory performance, particularly episodic memory, in healthy older adults with age-associated memory impairment.

Dosing Protocol

The most commonly studied dose in human clinical trials for cognitive support is 500–1,000 mg/day, typically taken orally in divided doses. It is often administered in the morning or early afternoon to avoid potential sleep disturbances.

Safety & Contraindications

CDP-choline is generally well-tolerated with a strong safety profile in human trials up to 1,000 mg/day. Mild adverse effects are rare but can include gastrointestinal distress, transient headaches, insomnia, or restlessness. It should be used with caution in individuals with a history of severe depression or bipolar disorder, as dopaminergic modulation may theoretically affect mood stability.

Quick Stats
Evidence TierTier I
Clinical Trials470
Typical Dose250 mg
Est. Cost/Day$0.34
Purity99.5%
Synergistic Compounds
UridineDHAPhosphatidylserineHuperzine A
Medical disclaimer: This page is for informational purposes only. Consult a qualified healthcare provider before starting any supplement regimen. Vitaei does not provide medical advice.